Development of a targeted BioPROTAC degrader selective for misfolded SOD1
Christen G. Chisholm(University of Wollongong), Justin J. Yerbury(University of Wollongong), Luke McAlary(University of Wollongong), Mikayla Brown(University of Wollongong), Kara L. Vine(University of Wollongong), Neil R. Cashman(University of British Columbia), Lars M. Ittner(Macquarie University), Heath Ecroyd(University of Wollongong), Emma‐Jayne Proctor(University of Wollongong), Darren N. Saunders(Garvan Institute of Medical Research), Jeremy S. Lum(University of Wollongong), Jody Gorman(University of Wollongong), Fabien Delerue(The University of Texas MD Anderson Cancer Center), Natalie E. Farrawell(University of Wollongong), Rachael Bartlett(University of Wollongong)
Cited by 5
Related Papers
Novel Mutations in TARDBP (TDP-43) in Patients with Familial Amyotrophic Lateral Sclerosis
|PLoS Genetics|2008|463
Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities
|Journal of Controlled Release|2018|297
Neuroprotective effects of apigenin against inflammation, neuronal excitability and apoptosis in an induced pluripotent stem cell model of Alzheimer’s disease
|Scientific Reports|2016|281
Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
|Anti-Cancer Agents in Medicinal Chemistry|2009|269
Walking the tightrope: proteostasis and neurodegenerative disease
|Journal of Neurochemistry|2016|238